Advanced search    

Search: authors:"Atsushi Sato"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,1 Shunichi Sugawara,2 Yasuo Saijo,3 Makoto Maemondo,4 Atsushi Sato,5 Shinzo Takamori,6 Taishi Harada,7 Tetsuro Sasada,8 Tatsuyuki Kakuma,9 Junji Kishimoto,10 Akira Yamada,11 Masanori

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,1 Shunichi Sugawara,2 Yasuo Saijo,3 Makoto Maemondo,4 Atsushi Sato,5 Shinzo Takamori,6 Taishi Harada,7 Tetsuro Sasada,8 Tatsuyuki Kakuma,9 Junji Kishimoto,10 Akira Yamada,11 Masanori

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

Background Metastatic colorectal cancer carries a poor prognosis and cannot be cured by currently available therapy. Chemotherapy designed to prolong survival and improve the quality of life (QOL) of patients is the mainstay of treatment. Standard regimens of FOLFOX/bevacizumab and CapeOX/bevacizumab can cause neurotoxicity, potentially disrupting treatment. The results of 3...